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Cellular immune response, specifically tumor infiltrating lymphocytes (TILs), has been
correlated to survival in epithelial ovarian cancer; however, specific gene expression patterns
for this response remain poorly understood. The objective of this research was to investigate
the prognostic and biologic significance of immune-related gene expression in high grade
serous ovarian cancer (HGSOC). To do so, a panel of immune related gene expression was
evaluated in HGSOC utilizing The Cancer Genome Atlas (TCGA) and validated in an
independent cohort of ovarian tumors. Based on the strong association with survival, the
cohort was grouped into LCK (lymphocyte specific tyrosine kinase) high and non-LCK high
tumors and profiles of gene expression and clinical information were obtained. We
demonstrate that mRNA upregulation of LCK was correlated with the strongest improvement
in survival of the genes investigated. When compared to previously validated metrics such as
cytolytic activity score (CYT), LCK proved to be a more discerning prognosticator across
tumor types available in the TCGA. In ovarian cancer, correlated gene enrichments were
notable for chemokine and immunoglobin complex related genes, ie B cell related transcripts.
Therefore, this research shows that LCK is a biomarker of prognostic and biological

importance, potentially due to its ability to capture the genomic signature of cooperative T
and B cell interaction. This provides essential support for further investigation into the role of
tumor infiltrating B cells (TIL-B) and tertiary lymphoid structures (TLS), from which
insights into this cooperation can be drawn. As ovarian cancer is the leading cause of death
from gynecologic malignancy, such insights have the potential to not only offer important
prognostic information but also may provide novel therapeutic approaches to the treatment of
this deadly disease.

TABLE OF CONTENTS
List of Tables ............................................................................................................................. i
List of Figures ........................................................................................................................... ii
List of Appendices ................................................................................................................... iii
Background ................................................................................................................................1
Literature Review.................................................................................................................1
Immunogenicity of Ovarian Cancer...............................................................................1
Genomic Biomarkers in Ovarian Cancer .......................................................................2
Genomic Prognostic Scoring Systems in Other Tumor Types ......................................4
Preliminary Data ..................................................................................................................5
Public Health Significance ...................................................................................................7
Hypothesis, Research Question, Specific Aims or Objectives ............................................8
Methods....................................................................................................................................10
Aim 1: Validate the association between LCK and survival in an independent
cohort of HGSOC samples via immunohistochemistry .........................................10
Study Design, Setting, and Study Population: .............................................................10
Data Collection and Analysis: .....................................................................................11
Statistical Analysis .......................................................................................................12
Human Subject Samples and Data Considerations ......................................................12
Aim 2: Compare the prognostic capability of LCK to previously validated
CYT score within the TCGA .................................................................................14
Study Design, Setting, and Study Population: .............................................................14
Data Collection and Analysis: .....................................................................................15
Statistical Analysis .......................................................................................................15
Human Subject Samples and Data Considerations ......................................................16
Journal Article..........................................................................................................................17
Title: Lymphocyte-Specific Kinase Expression is a Prognostic Indicator in
Ovarian Cancer and Correlates with a Prominent B-Cell
Transcriptional Signature .......................................................................................17
Journal: Cancer Immunology, Immunotherapy (CII) ........................................................17
Conclusion ...............................................................................................................................34

Tables .......................................................................................................................................37
Table 1: Demographics by LCK Expression Level ...........................................................37
Table 2: Survival Analyses Comparing the Prognostic Ability of LCK and
CYT........................................................................................................................38
Table 3: Gene Ontology Enrichment in Selected Subset (LCK High) ..............................40
Figures......................................................................................................................................41
Figure 1: TCGA Analysis of Immune-related Gene Expression .......................................41
Figure 2: Kaplan Meier Analysis Comparing Prognostic Aability of LCK and
CYT........................................................................................................................42
Figure 3: LCK Expression and Survival Analysis in an Independent Cohort ...................43
Appendices ...............................................................................................................................44
Appendix A: Top Overexpressed Genes in LCK High Samples .......................................44
Appendix B: LCK Expression in Benign and Malignant Tissue ......................................45
References ................................................................................................................................46

LIST OF TABLES
Table 1: Demographics by LCK Expression Level ...........................................................37
Table 2: Survival Analyses Comparing the Prognostic Ability of LCK and
CYT........................................................................................................................38
Table 3: Gene Ontology Enrichment in Selected Subset (LCK high) ...............................40

i

LIST OF FIGURES
Figure 1: TCGA Analysis of Immune-related Gene Expression .......................................41
Figure 2: Kaplan Meier Analysis comparing Prognostic Ability of LCK and
CYT........................................................................................................................42
Figure 3: LCK Expression and Survival Analysis in an Independent Cohort ...................43

ii

LIST OF APPENDICES
Appendix A: Top Overexpressed Genes in LCK High Samples .......................................44
Appendix B: LCK Expression in Benign and Malignant Tissue .......................................45

iii

BACKGROUND
Literature Review
Immunogenicity of Ovarian Cancer
There is growing evidence to support a pivotal role of the immune system in the pathogenesis
of cancer; in high grade serous ovarian cancer (HGSOC) and other cancers the presence of
high levels of tumor infiltrating lymphocytes (TILs) has been associated with improved
progression free survival (PFS) and overall survival (OS) [1]–[7]. TIL infiltration of
treatment naïve tumors was associated with a significantly improved median progression free
(22.4 vs 5.8 months, p < 0.001) and overall survival (50.3 vs 18.0 months, p < 0.001)
compared to tumors with no T-cells present [7]. Additionally, expression of alternative
markers of activation of the immunoreactivity, including upregulation of programmed-death
ligands 1 and 2 (PD-L1 and PD-L2), has also been shown to correlate with improved OS [8].
Recent publications reported a histotype-specific nature of immune infiltration and
demonstrated the magnitude of survival benefit in ovarian cancer was dose dependent on
CD8 positive TILs [9], [10].

However, the use of TIL classification by immunohistochemistry (IHC) for clinical decisionmaking currently remains in its early stages, as IHC can be time intensive and requires
comparatively specialized pathology input. Additionally, while prognostic ability is useful,
ideally biomarkers should also be relevant to predict response to therapy. For example, the
use of PDL1 staining has emerged as an intuitive marker for prediction of response to
immune checkpoint inhibitors, at least in some cancers. Immune checkpoint inhibitors are a
1

novel class of drugs which are monoclonal antibodies that block PD-1/PDL-1 and result in
increased immune response to tumor. These drugs have revealed efficacy in 10-15% of
heavily pretreated ovarian malignancies with some durable responses [11]–[15]. However,
given the low response rates and significant toxicities of such therapies, studies aimed at
identifying factors to provide more personalized prognostication for response to these
therapies in particular are of utmost importance. However, the predictive accuracy of IHC
markers to determine response to immune checkpoint therapy for ovarian cancer remains
unknown, as many trials remain ongoing and have not yet reported translational endpoints. It
is worth mentioning that the reported response rates to PD1/PDL1 targeting drugs are not
appreciably higher in clinical trials using PDL1 positivity by IHC as an eligibility criterion
[26]. Given the difficulties presented with IHC analyses, investigation into genomic markers
represents an exciting potential alternative, but have thus far yielded mixed results.

Genomic Biomarkers in Ovarian Cancer
The biological basis and the identification of reliable genomic markers with prognostic
significance have proven elusive. Multiple studies have attempted to identify gene expression
signatures and their predictive ability for clinical outcome, including overall survival, time to
relapse or response to chemotherapy [16]–[21]. However, gene expression models have thus
far been limited by complexity, often requiring large and heterogeneous gene signatures in
order to demonstrate prognostic ability. For example, one study using an analysis of 68
HGSOC samples validated a 115 gene signature, termed the Ovarian Cancer Prognostic
Profile (OCPP) [21]. When attempting to classify included relevant genes by function, 17
2

different function groups were required and included both immune-related function,
angiogenesis pathways, and cell-cell adhesion signaling related to tumor epithelialmesenchymal transition. Discrete biologic etiologies for predictive ability is limited with
such heterogeneity.

There are very few studies which used unsupervised classification approaches, thus prior
classification has previously been subject to inherent bias in grouping determinations.
Approaches to such unbiased categorization have been limited by sample size and by
inclusion of heterogeneous histologic ovarian tumor subtypes [22]–[24]. Perhaps the most
comprehensive of such unsupervised clustering research analyzed 285 samples, including
both high grade serous and endometrioid tumors [16]. Optimal clustering of array data
revealed six different molecular subtypes, which were clinically relevant as they grouped by
histologic subtype and clinical outcome. However, each subtype displayed distinct levels of
immune cell infiltration and reactive stroma gene expression signatures, making it difficult to
determine driver biologic pathways.

Based on these subtypes, the original publication of the ovarian cancer TCGA analysis
attempted to categorize samples into more biologically based functional groups [25]. The
investigators identified an “immunoreactive” group as one of the four subtypes of high-grade
serous ovarian cancer based on transcriptional profiling. In this analysis, T-cell chemokine
ligands, CXCL11 and CXCL10, and the receptor, CXCR3, characterized the immunoreactive
subtype. Unfortunately, there was no prognostic impact on survival associated with this
3

immunoreactive subtype [25]. There is a critical unmet need to establish reliable genomic
biomarker(s) for this tumor immune response with utility in prognostication and stratification
of untreated ovarian cancers.

Genomic Prognostic Scoring Systems in Other Tumor Types
Investigation of such genomic biomarkers can be informed by research in alternate tumor
types and then applied to HGSOC. One well published genomic prognostic feature is the
cytolytic activity score (CYT), a quantitative measure of immune cytolytic activity based on
transcript levels of perforin (PRF1) and granzyme A (GZMA) [11]. These two molecules
reflect the central mechanism for cytotoxic lymphocyte killing; perforin is responsible for the
creation of pores within the target cell membrane which then allow for the entry of
granzymes that cleave caspases and induce apoptosis. CYT has been shown to be a useful
metric of cyototoxic activation and subsequent improved survival in multiple other tumor
types [11], [26]–[28].

In pancreatic cancer, a study of expression data from 134 tumors available in The Cancer
Genome Atlas (TCGA) revealed that CYT-high tumors exhibit increased expression of
multiple immune checkpoint related genes, and, interestingly, were inversely correlated with
genomic alterations, indicating that intrinsic oncogenic processes drive immune suppression.
However, this analysis did not report a relationship of CYT score subsets to clinical outcome
and prognosis [27]. Similarly, an analysis of CYT in colorectal cancer demonstrated that
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CYT-high tumors were associated with high levels of activated T-cells but did perform
subsequent analysis in order to report improved overall survival in this tumor subset[26].

The definition of cut-off points for CYT-high and CYT-low tumors is not standardized
across tumor types. In the above literature regarding pancreatic cancer, CYT was defined as
top 10 percentile compared to bottom 25th percentile [27]. In colorectal, the threshold for
dichotomization was determined at multiple candidate cut-points and the cut-off point that
gave the most significant results was chosen [26]. A meta-analysis, performed across tumor
subtypes within the TCGA, including ovarian cancer, found very diverse levels of CYT
across different cancer types. Results were not dichotomized or clustered and instead were
correlated as a continuous variable to various markers of immunoreactivity, namely immune
checkpoint molecules and TILs [28].

CYT score has not been independently studied in ovarian malignancy; further description of
this score specifically in HGSOC is needed. Additionally, based on the meta-analysis by
Roufas et al, this score can serve as a benchmark against which other proposed genomic
biomarkers can be evaluated.

Preliminary Data
To address this unmet need to establish genomic biomarkers in ovarian malignancy, we
undertook a preliminary study in which we analyzed 535 high grade serous ovarian samples
in the TCGA dataset using the cBioPortal platform, 520 of which had Affymetrix U133
5

microarray data available for mRNA analysis [25], [29], [30]. Analysis of the TCGA was
performed investigating the upregulation of a panel of immune related genes including:
CD3E, CD3D, CD2, CD4, Perforin 1 (PRF1), Granzyme A (GZMA), CD19, and CD20
(MS4A1) and LCK (Figure 1). CD8A data was unavailable within the microarray.
Progression free and overall survival data were collected for each of the above genes and
compared in elevated and non-elevated samples.

LCK (lymphocyte specific tyrosine kinase) was shown to have the strongest association with
survival; patients with high LCK mRNA expression had a median progression free survival
of 29.4 months, compared to 16.9 in those without high LCK expression (p=0.003). Patients
with high LCK had significantly longer overall survival than non-LCK high with median
overall survival time of 95.1 months and 44.5 months, respectively (p= 0.001). Only two
other markers chosen were statistically significantly associated with survival and shown to
have less dramatic prognostic differences. High expression of B-cell marker CD20 (MS4A1)
was associated with survival, with median PFS of 27.2 months (p= 0.08) and overall survival
of 86.1 months (p=0.02), while CD3E elevation had a significant association with PFS
(p=0.016) but was not associated with OS (p=0.330). High expression of the other immune
related genes tested above was not associated with survival.

This stringent high criteria for mRNA expression in LCK was found in 23 (4%) of all cases
(Figure 1). We also evaluated potential demographic, clinical, and pathological differences
between LCK high and remaining samples (Table 1). The median age of the entire cohort
6

was 59 years old (30-89 years), and most patients were advanced stage (72.9 % stage IIIC,
16.0% stage IV). No differences were detected between the two groups with respect to
clinical characteristics, including age, race, ECOG performance status, clinical stage, and
tumor grade.

These data demonstrate LCK expression has the potential to be a clinically important
prognostic indicator in ovarian malignancy. LCK likely broadly captures the
immunoreactivity of a tumor and thus is a less heterogeneous biologic marker than those
previously studied, which have included both immune pathways as well as cell adhesion
signaling and/or angiogenic molecular indicators. This simplicity is valuable as it may be
more easily evaluated to frame further biologic hypotheses, especially within the context of
HGSOC response to treatment options which rely on this immunoreactivity, such as immune
checkpoint inhibitors.

Public Health Significance
High grade serous ovarian cancer (HGSOC) is the leading cause of death from
gynecologic malignancy, with over 22,000 cases per year in the United States and over
14,000 deaths [31]. The high mortality rate is due to the fact the majority of ovarian cancer
presents at advanced stage III/IV and has a high risk of recurrence despite initial response to
traditional platinum based therapy. These patients are treated with a large and everexpanding amount of healthcare resources such as hospitalizations, surgical treatment, and
chemotherapeutic regimens. Additionally, novel treatment options such as immune
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checkpoint inhibitors, which leverage the immune-reactive nature of this malignancy, are
rapidly expanding in use but are also currently nearly prohibitively expensive [32], [33].
There is no currently available effective screening method for ovarian cancer, thus
primary prevention options remain limited [34]. Public health interventions must focus
instead on secondary prevention, with early detection and improved prognostication, as well
as tertiary prevention to reduce morbidity and recurrence. The identification of relevant
clinically applicable biomarkers will allow for better patient counseling regarding prognosis
and more educated decision-making regarding treatment planning. Additionally, the potential
for selection of treatment based on a biomarker predicted response has the promise to
drastically improve both treatment selection and, consequently, treatment efficacy.
The current study contributes meaningfully to this gap in knowledge. As IHC markers
of immunogenicity have not yet proved clinically useful, the current study uses the known
TIL correlation with survival, to delve more deeply into potential immune related gene
expression biomarkers. We capitalize on preliminary data obtained by the current
investigator, which identifies LCK as a particularly valuable biomarker. The current study
provides essential validation of these findings and better characterization of LCK’s utility as
compared to previously validated markers such as CYT score.

Hypothesis, Research Question, Specific Aims or Objectives
Tumor infiltrating lymphocytes (TILs) are correlated with better prognosis in high grade
serous ovarian cancer (HGSOC); however, specific gene expression patterns for this response
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remain poorly understood. There is a critical unmet need to establish such genomic
biomarkers within this deadly gynecologic malignancy.
Preliminary data demonstrates LCK correlates with both progression free and overall
survival in available TCGA samples. Therefore, we hypothesized this prognostic ability of
LCK would be validated by protein-expression as evaluated by IHC in an independent
cohort of HGSOC samples. We additionally hypothesized LCK would prove to be a
better predictor of survival than cytolytic activity score (CYT) in HGSOC.
We investigated these independent hypotheses via the following specific aims:
Aim 1: Validate the association between LCK and survival in an independent cohort
of HGSOC samples via immunohistochemistry
Aim 2: Compare the prognostic capability of LCK to previously validated CYT score
within the TCGA
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METHODS
The high grade serous ovarian cancer (HGSOC) provisional data set from the TCGA was
analyzed to explore the correlation between a panel of immune cell markers and clinical
outcome [18]. For mRNA expression analysis, Affymetrix U133 microarray data was used
and only samples for which these data were available included. Samples were divided into
“high expression” and “non-high expression” groups using the Cbioportal web interface, for
the following markers: CD2, CD3E, CD3D, CD4, GZMA, PRF1, CD19, MS4A1 and LCK
[19], [20] where high expression was defined as expression within the top 3% (1.86 SD). As
described in the background, LCK was demonstrated to significantly predict both progression
free and overall survival. The current study represents the subsequent analyses of this same
data required to validate this finding and further explore the value of LCK as a prognostic
biomarker.

Aim 1: Validate the association between LCK and survival in an independent cohort of
HGSOC samples via immunohistochemistry
Study Design, Setting, and Study Population:
LCK protein expression was determined via immunohistochemistry on an independent cohort
of 72 ovarian cancer samples using a commercially available anti-LCK antibody
(HPA003494, Sigma-Aldrich). Additionally, CD8 (T-cell marker) and CD20 (B-cell marker)
immunohistochemistry staining was performed in this cohort (CD20:SAB5600082, SigmaAldrich, CD8: CD8-4B11-L-CE, Leica Biosystems), and demographics and survival data
were abstracted.
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Additionally, IHC was performed across a range of benign and malignant serous neoplasms
on an available tissue microarray (TMA). The TMA contained a spectrum of serous
gynecological tissues, including normal fallopian tube epithelium obtained at the time of
salpingo-oophorectomy for benign ovarian cystadenomas and high grade serous carcinomas.
It included a total of 20 normal fallopian tube samples, 14 high grade ovarian serous
carcinoma tissues, and 13 benign serous cystadenomas. Each tissue specimen was
represented as 3 independent cores on the TMA.

Data Collection and Analysis:
A semi-quantitative IHC score was assigned and evaluated by the investigator, with
confirmation by pathology collaborators including a senior gynecologic pathologist. LCK
status of these samples was unknown, therefore all parties were initially blinded to outcome.
For scoring purposes, tissue LCK+ lymphocytes staining was classified as none (0, average
of one or less LCK+ lymphocyte), low (1, less than 10 LCK+ lymphocytes), medium (2,
greater than 10 but less than 40 LCK+ lymphocytes), and high (3, greater than 40 LCK+
lymphocytes or multiple germinal centers). The same cut offs were used for CD8 and CD20
positivity. The counts were averaged over 3 fields for independent pathology samples or
averaged over the 3 cores for TMA samples.
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Statistical Analysis
IHC score comparison was performed using the Mann-Whitney U test with p<0.05
considered significant. Spearman correlations were performed to assess the strength of
association of LCK, CD20, and CD8. Strength of correlations analysis was performed using
R version 3.4.1 package “cocor” [21].

The sample size was pre-defined by availability of tumor samples; there were 72 HGSOC
samples available for analysis. TCGA data in preliminary analysis demonstrated an
improvement in survival from 16.9 months to 29.4 months for those with high LCK
expression. Therefore, we assumed a similar doubling of survival in our validation cohort.
However, preliminary data used a very stringent definition (top 3%) of high LCK expression,
and IHC analysis is unable to have this level of specificity or discriminatory capacity.
Therefore, based on prior literature in other tumor types and the known immunogenicity of
ovarian malignancy, we estimated that approximately 30% of tumors would be LCK-high
using the much less stringent IHC scoring metric. At a significance level of 0.05, with this
expected ratio of 30% and assumed doubling of median survival, the 72 samples available
provided a 74% power to detect a difference between LCK-high and non-LCK-high tumors.

Human Subject Samples and Data Considerations
Patients included in this study are a subset of patients with HGSOC who sought treatment at
The University of Texas MD Anderson Cancer Center (MDACC). Eligibility required
pathologic confirmation at MDACC and availability of sample tissue blocks within the
12

Gynecologic Oncology Tumor Bank. All patient samples were collected on a tissue banking
protocol approved by MDACC Institutional Review Board (IRB) (LAB06-0412). The
included 72 samples are a previously established sample subset available in the lab of Dr.
Samuel Mok, who provided consent for their use for the current project. Clinical information
for this subset of patients was also previously collected in Dr. Mok’s lab.

The current analysis represents a retrospective IHC analysis of these blocks and correlation
with clinical data, without additional patient contact or intervention. Therefore, this study did
not involve any additional testing, treatment or biopsy procedures. Retrospectively, it would
be impractical to obtain consent from patients who may be lost to follow-up, no longer in
treatment or have died, therefore, the current study was performed under a waiver of
informed consent.

All data collected is confidential and used only for research purposes. The data resides on
the secure, password protected, 21CFR part 11 compliant database. Subjects were not
identified by name during data entry and analysis. Subject names do not appear in any report
or paper related to the study. Only the investigator and collaborators (including PI, Dr Amir
Jazaeri, and Dr. Samuel Mok) have access to the data. Unique study numbers have replaced
the HIPAA identifiers in the analytical file.
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Aim 2: Compare the prognostic capability of LCK to previously validated CYT score
within the TCGA
Study Design, Setting, and Study Population:
Similar to preliminary data, the high grade serous ovarian cancer (HGSOC) provisional data
set from The Cancer Genome Atlas was analyzed [18]. For mRNA expression analysis,
complete RNA sequencing data, rather than Affymetrix microarray data, was used for
analyses to be performed across 30 tumor types available in the TCGA. The following tumor
types (project code and n=sample size) were included: adrenocortical carcinoma (ACC,
n=92), bladder/urothelial (BLCA, n=412), breast invasive carcinoma (BRCA, n=1098),
cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC, n=307),
cholangiocarcinoma (CHOL, n=51), colon adenocarcinoma (COAD, n=461), esophageal
carcinoma (ESCA, n = 185), glioblastoma multiforme (GBM, n=617), head and neck
squamous cell carcinoma (HNSC, n=528), kidney renal clear cell carcinoma (KIRC, n=537),
kidney renal papillary cell carcinoma (KIRP, n=291), acute myeloid leukemia (LAML,
n=200), low grade glioma (LGG, n=516), liver hepatocellular carcinoma (LIHC, n=377),
lung adenocarcinoma (LUAD, n = 585), lung squamous cell carcinoma (LUSC, n=504),
mesothelioma (MESO, n=87), ovarian serous cystadenocarcinoma (OV, n=608), pancreatic
adenocarcinoma (PAAD, n=185), pheochromocytoma and paraganglioma (PCPG, n=179),
prostate adenocarcinoma (PRAD, n=500), rectum adenocarcinoma (READ, n=172), sarcoma
(SARC, n=261), skin cutaneous melanoma (SKCM, n=470), stomach adenocarcinoma
(STAD, n=443), testicular germ cell tumors (TGCT, n=150), thyroid carcinoma (THCA,

14

n=507), uterine corpus endometrial carcinoma (UCEC, n=560), uterine carcinosarcoma
(UCS, n=57), and uveal melanoma (UVM, n=80).

Data Collection and Analysis:
For this analysis in each cancer the LCK-high expressing population (the top 10%) was
compared to the LCK-low population (bottom 10% in expression). The definition of high and
low expressing samples was broadened from the stringent top 3% used in the preliminary
analysis to make results more generalizable to a broader population of ovarian malignancy.

LCK prognostic capacity was compared to CYT, which has been previously defined [14].
Briefly, to calculate CYT score, total raw read counts per gene were converted to transcripts
per million (TPM), which were calculated by dividing by the gene's maximum transcript
length to provide a coverage depth estimate and scaling to sum to a total depth of 1e6 per
sample. CYT was then calculated as the geometric mean of GZMA and PRF1 expression
values in TPM. As dichotomization of CYT-high and CYT-low is nonstandardized across
prior literature, we defined high and low CYT groups as top 10% and bottom 10% for
comparison, in order to parallel the LCK definition most exactly.

Statistical Analysis
Descriptive statistics (n, percent, mean, standard deviation) were calculated to summarize
patient demographics. Cox regression and backwards stepwise regressions were performed
to assess overall survival (OS) and progression free survival (PFS) for LCK gene expression
15

and dichotomized CYT groups. Correction for multiple comparisons was performed using
Bonferroni method. Statistical analyses were performed using SAS 9.4 for Windows (SAS
Institute Inc., Cary, NC).

Human Subject Samples and Data Considerations
To address this aim, analyses mirrored what was performed to provide the preliminary data.
Specifically, the high grade serous ovarian cancer (HGSOC) provisional data set from The
Cancer Genome Atlas was analyzed [18]. This is a publicly available dataset that is queryable via the cBioPortal web interface [19], [20]. This cBioPortal for Cancer Genomics was
originally developed at Memorial Sloan Kettering Cancer Center (MSK), and is hosted by the
Center for Molecular Oncology at MSK. The software is available under an open source
license and is maintained by a multi-institutional team, consisting of MSK, the Dana Farber
Cancer Institute, Princess Margaret Cancer Centre in Toronto, Children's Hospital of
Philadelphia, The Hyve in the Netherlands, and Bilkent University in Ankara, Turkey.

The proposed analysis represents additional analysis of this publically available data, thus
does not involve any HIPAA identifiers. No additional consent is required for data usage,
apart from appropriate citation of data source in any subsequent manuscript publication.
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Abstract:
Objective: To investigate the prognostic and biologic significance of immune-related gene
expression in high grade serous ovarian cancer (HGSOC).
Methods: Gene expression dependent survival analyses for a panel of immune related genes
were evaluated in HGSOC utilizing The Cancer Genome Atlas (TCGA). Prognostic value of
LCK (lymphocyte specific tyrosine kinase) was validated using immunohistochemistry
(IHC) in an independent set of 72 HGSOC. Prognostic performance of LCK was compared
to cytolytic score (CYT) using RNAseq across multiple tumor types. Differentially expressed
genes in LCK high samples and gene ontology enrichment were analyzed.
Results: High pre-treatment LCK mRNA expression was found to be a strong predictor of
survival in a set of 535 ovarian cancers. Patients with high LCK mRNA expression had a
longer median progression free survival (PFS) of 29.4 months compared to 16.9 months in
those without LCK high expression (p=0.003), and longer median overall survival (OS) of
95.1 months versus 44.5 months (p= 0.001), which was confirmed in an independent cohort
by IHC (p=0.04). LCK expression was compared to CYT across tumor types available in the
TCGA and was a more significant predictor of prognosis in HGSOC. Unexpectedly, LCK
high samples also were enriched in numerous immunoglobulin-related and other B cell
transcripts.
Conclusions: LCK is a better prognostic factor than CYT in ovarian and other cancers. In
HGSOC, LCK high samples were characterized by higher expression of immunoglobulin and
B cell related genes suggesting a cooperative interaction between tumor infiltrating T and B
cells may correlate with better survival in this disease.
18

Introduction
Ovarian cancer is the leading cause of death from gynecologic malignancy, with over 22,000
cases per year in the United States and over 14,000 deaths [1]. The high mortality rate is due
to the fact that the majority of ovarian cancer presents at advanced stage III/IV and has a high
risk of recurrence despite initial response to traditional platinum based therapy. There is
growing evidence to support a pivotal role of the immune system in the pathogenesis of
cancer; in ovarian cancer and others the presence of high levels of tumor infiltrating
lymphocytes (TILs) has been associated with improved PFS and OS [2]–[8]. However, this
impact is in the context of a complex interplay between multiple aspects of the tumor
microenvironment, as T cell type, location, and tumor stromal factors have all been shown to
modify survival rates [5], [9]–[13].

In the setting of this complexity, there is a need for reliable biomarker(s) with utility in
prognostication and stratification of untreated ovarian cancers. One well published genomic
prognostic feature is the cytolytic activity score (CYT), a quantitative measure of immune
cytolytic activity based on transcript levels of perforin (PRF1) and granzyme A
(GZMA)[14]. These two molecules reflect the central mechanism for cytotoxic lymphocyte
killing; perforin is responsible for the creation of pores within the target cell membrane
which allow for the entry of granzymes that cleave caspases and induce apoptosis. CYT has
been shown to be a useful metric of cyototoxic activation and subsequent improved survival
in multiple tumor types [14]–[17]. Therefore, the objective of this study was to investigate a
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panel of immune-related genes to determine their prognostic ability and compare to these
previously validated metrics.

Materials and Methods
TCGA Data Analysis
To explore the correlation between a variety of immune cell markers and clinical outcome,
the high grade serous ovarian cancer (HGSOC) provisional data set from the TCGA was
analyzed [18]. Because all information from the TCGA is de-identified and publically
available, informed consent by the study participants and approval of an ethics committee
were unnecessary to perform this portion of the study. For mRNA expression analysis,
Affymetrix U133 microarray data was used and only samples for which these data were
available included. Samples were divided into “high expression” and “non-high expression”
groups using the Cbioportal web interface, for the following markers: CD2, CD3E, CD3D,
CD4, GZMA, PRF1, CD19, MS4A1 and LCK [19], [20] where high expression was defined
as expression within the top 3% (1.86 SD). Gene expression and enrichment analyses were
performed using BRB-ArrayTools (Version 4.5.1) developed by Dr. Richard Simon and the
BRB-ArrayTools Development Team. Gene expression analysis was performed with
p<0.001 cutoff for significance to guard against false discovery due to multiple comparisons
and at least two-fold difference in the geometric mean of expression levels.

Subsequent analysis of RNA sequencing data was performed across 30 tumor types available
in the TCGA. The following tumor types (project code and n=sample size) were included:
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adrenocortical carcinoma (ACC, n=92), bladder/urothelial (BLCA, n=412), breast invasive
carcinoma (BRCA, n=1098), cervical squamous cell carcinoma and endocervical
adenocarcinoma (CESC, n=307), cholangiocarcinoma (CHOL, n=51), colon adenocarcinoma
(COAD, n=461), esophageal carcinoma (ESCA, n = 185), glioblastoma multiforme (GBM,
n=617), head and neck squamous cell carcinoma (HNSC, n=528), kidney renal clear cell
carcinoma (KIRC, n=537), kidney renal papillary cell carcinoma (KIRP, n=291), acute
myeloid leukemia (LAML, n=200), low grade glioma (LGG, n=516), liver hepatocellular
carcinoma (LIHC, n=377), lung adenocarcinoma (LUAD, n = 585), lung squamous cell
carcinoma (LUSC, n=504), mesothelioma (MESO, n=87), ovarian serous
cystadenocarcinoma (OV, n=608), pancreatic adenocarcinoma (PAAD, n=185),
pheochromocytoma and paraganglioma (PCPG, n=179), prostate adenocarcinoma (PRAD,
n=500), rectum adenocarcinoma (READ, n=172), sarcoma (SARC, n=261), skin cutaneous
melanoma (SKCM, n=470), stomach adenocarcinoma (STAD, n=443), testicular germ cell
tumors (TGCT, n=150), thyroid carcinoma (THCA, n=507), uterine corpus endometrial
carcinoma (UCEC, n=560), uterine carcinosarcoma (UCS, n=57), and uveal melanoma
(UVM, n=80). For this analysis in each cancer, the LCK-high expressing population (the top
10%) was compared to the LCK-low population (bottom 10% in expression). This was
compared to CYT which has been previously defined [14]. Briefly, total raw read counts per
gene were converted to transcripts per million (TPM), which was calculated by dividing by
the gene's maximum transcript length to provide a coverage depth estimate and scaling to
sum to a total depth of 1e6 per sample. CYT was calculated as the as the geometric mean of
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GZMA and PRF1 expression values in TPM, where similar high (top 10%) and low (bottom
10%) groups were compared.

Immunohistochemistry (IHC)
LCK protein expression was performed using immunohistochemistry on an independent
cohort of 72 ovarian cancer samples using a commercially available anti-LCK antibody
(HPA003494, Sigma-Aldrich). Additionally, CD8 and CD20 immunohistochemistry staining
was performed in this cohort (CD20:SAB5600082, Sigma-Aldrich, CD8: CD8-4B11-L-CE,
Leica Biosystems), and demographics and survival data was abstracted. All tumor tissue
samples were collected under a protocol approved by MD Anderson Cancer Center
Institutional Review Board. They were resected from the primary tumor site of previously
untreated HGSOC patients with stage 3 and 4 diseases. A semi-quantitative IHC score was
assigned by pathology collaborators including a senior gynecologic pathologist (C.P., M.S.),
and as LCK status of the sample was not previously tested both pathologists were inherently
blinded. For scoring purposes tissue LCK+ lymphocytes staining was as none (0, average of
one or less LCK+ lymphocyte), low (1, less than 10 LCK+ lymphocytes), medium (2, greater
than 10 but less than 40 LCK+ lymphocytes), and high (3, greater than 40 LCK+
lymphocytes or multiple germinal centers). The same cut offs were used for CD8 and CD20
positivity, and the counts were averaged over 3 fields for independent pathology samples.

IHC was additionally performed across a range of benign and malignant serous neoplasms on
a tissue microarray (TMA), where counts were averaged over the 3 cores. All tissue was
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obtained under an IRB approved protocol at the University of Virginia, and the TMA
contained a spectrum of serous gynecological tissues, including normal fallopian tube
epithelium obtained at the time of salpingo-oophorectomy for benign ovarian cystadenomas
and high grade serous carcinomas. A total of 20 normal fallopian tube samples, 14 high grade
ovarian serous carcinoma tissues, and 13 benign serous cystadenomas were compared. Each
tissue specimen was represented as 3 independent cores on the TMA.

Statistical analysis
Descriptive statistics (n, percent, mean, standard deviation) were calculated to summarize
patient demographics. Cox regression and backwards stepwise regressions were performed
to assess OS and PFS for immune-related genes and dichotomized CYT groups. Statistical
analyses were performed using SAS 9.4 for Windows (SAS Institute Inc., Cary, NC). IHC
score comparison was performed using the Mann-Whitney U test with p<0.05 considered
significant. Spearman correlations assessed the strength of association of LCK, CD20, and
CD8. Strength of correlations analysis was performed using R version 3.4.1 package “cocor”
[21].

Results
High LCK expression predicts improved survival in HGSOC
A total of 535 high grade serous ovarian samples in the TCGA dataset were included using
the cBioPortal platform, 520 of which had Affymetrix U133 microarray data available for
mRNA analysis [18]–[20]. Analysis of the TCGA was performed investigating the
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upregulation of immune related genes including CD3E, CD3D, CD2, CD4, Perforin 1
(PRF1), Granzyme A (GZMA), CD19, and CD20 (MS4A1) and LCK (Figure 1). Of note,
CD8A data were unavailable within the TCGA microarray dataset. High LCK mRNA
expression was present in 23 (4%) of all cases (Figure 1). Progression free and overall
survival data were collected for each of the above genes and compared in elevated and nonelevated samples. LCK was shown to have the strongest association with survival; patients
with high LCK mRNA expression had a median progression free survival of 29.4 months,
compared to 16.9 in those without high LCK expression (p=0.003). Similarly, patients with
high LCK had significantly longer overall survival than non-LCK high with median overall
survival time of 95.1 months and 44.5 months respectively (p= 0.001). As expected, LCK
mRNA high samples also had significantly higher LCK protein levels as determined by
reverse phase protein arrays (RPPA). Only two other markers within the panel were
statistically significantly associated with survival and were shown to have less dramatic
prognostic differences. Specifically, high expression of B-cell marker CD20 (MS4A1) was
associated with survival, with median PFS of 27.2 months (p= 0.08) and overall survival of
86.1 months (p=0.02), while CD3E elevation had a significant association with PFS
(p=0.016) but was not associated with OS (p=0.330). High expression of the other immune
related genes tested above was not associated with survival.

To examine if high LCK expression was simply a marker of high levels of tumor infiltrating
lymphocytes (TIL), we compared the levels of CD3 and TCR related transcripts in LCK high
samples. We also evaluated potential demographic, clinical, and pathological differences
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between LCK high and remaining samples (Table 1). The median age in the entire cohort
was 59 years old (30-89 years), and most patients were advanced stage (72.9 % stage IIIC,
16.0% stage IV). No differences were detected between the two groups with respect to
clinical characteristics, including age, race, ECOG performance status, clinical stage, and
tumor grade. LCK expression was correlated with high expression of CD3 and TCR related
transcripts, but as described above LCK had improved discriminatory prognostic ability than
these markers alone.

Given the dramatic improvement in survival demonstrated in LCK-high samples, the
influence of other established prognostic factors was tested in a Cox multivariable model that
included LCK status, age, race (white vs other), stage, grade, and ECOG status. LCK status
(p=0.021, HR=0.508) and race (p=0.024, HR = 0.657) were independent predictors of
survival, ie reduced the risk of progression event. Additionally, LCK mRNA level improved
OS (p=.001; HR=.315), as did race (p=.038; HR=.676) while age (p<.001; HR=1.026)
increased the risk of death event.

High LCK does not correlate to increased mutation number
Non-synonymous somatic mutations in malignancies can lead to expression of “neoepitopes” and hence increased potential immunogenicity, thus the relationship between LCK
levels and number of somatic mutations in high grade serous ovarian cancer samples was
evaluated. High mutation load, as defined by mutation count > 100, was present in 18 out of
520 tumors with sequencing data available (3.5%). To determine a possible relationship
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between mutational load and LCK expression, the number of somatic mutations in LCK high
samples was compared to that of non-LCK high tumors. This revealed no significant
difference in mutation load or copy number alteration based on LCK expression status
(Figure 1). In fact, in the LCK high samples, there was only one tumor with a mutation
count greater than 100 (4.3% of the LCK high group).

LCK is a more significant prognostic predictor than CYT in ovarian cancer and many other
malignancies
For this analysis, the definition of LCK high samples was liberalized (top 10%) and survival
was compared to low LCK (bottom 10%) within the TCGA in order to reduce selection bias
due to small numbers of LCK high/low cases. The median OS in the LCK high group was
52.6 months, as compared to 35.3 months in the LCK low group (p=0.00898). Similar
dichotomization of CYT, a measure of transcript levels of perforin (PRF1) and granzyme A
(GZMA), was performed; samples were grouped by CYT score into highest and lowest 10%.
CYT did not predict survival, with median OS was 49.4 and 52.8 months in high and low
cohorts respectively (p = 0.664). Kaplan-Meier curves can be found in Figure 2.

This analysis was performed for 30 tumor types available in TCGA (Table 2). Of these 30
cancer types, CYT was a significant predictor of overall survival in 5 cancers including:
breast invasive carcinoma (BRCA, p=0.00293), cervical carcinoma (CESC, p = 0.0121), low
grade glioma (LGG, p = 0.0112), sarcoma (SARC, p = 0.0323), and cutaneous melanoma
(SKCM, p = 0.00509). The LCK high group also had statistically significant improved
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survival in these subtypes (BRCA p=0.0546, CESC p= 0.000748, LGG p = 0.0269, SARC p
= 0.0166, and SKCM p =0.0271). Interestingly, high LCK expression also had improved
overall survival in an additional 3 cancer subtypes, namely: ovary as described above, head
and neck squamous carcinoma (HNSC, p = 0.0496), and uterine carcinosarcoma (UCS, p =
0.0358). Therefore, LCK was a more discerning predictor in tumor types where CYT was
predictive of OS, and it was additionally prognostic in a further subset of tumor types where
CYT was not.

LCK protein expression independently confirms impact on prognosis
In order to determine if there was concordance between high LCK mRNA and protein
expression we investigated LCK protein levels in samples designated as LCK-high by
mRNA expression in the TCGA cohort using reverse phase protein arrays (RPPA). As
expected, the LCK-high mRNA samples also expressed significantly higher levels of LCK
protein. We also used an independent validation cohort of 72 high grade serous ovarian
cancer samples with available clinical data to compare LCK protein expression using IHC
with CD8, and CD20 (markers of cytotoxic Tlymphocytes and B-cells, respectively). This
analysis confirmed that LCK expression was specific to tissue lymphocytes and that there
was no confounding LCK expression by normal epithelial or by tumor cells. Furthermore,
survival analysis revealed that only high LCK staining significantly increased overall
survival, with median survival for high LCK staining of 40.5 months compared to 27.0
months (p=0.04, Figure 3). Neither LCK intensity nor LCK distribution (focal or diffuse)
resulted in further stratification of the impact of LCK on survival.
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Transcriptional profile differs in LCK high samples
Given the prognostic importance of high LCK expression, we used the availability the U133
microarray data as part of the TCGA dataset to evaluate gene expression differences between
LCK-high expressing (n=23) and remaining samples (n=496). This analysis revealed 291
differentially expressed transcripts (at a statistical cut-off of P<0.001 and at least twofold
change). As expected, LCK-high samples were characterized by higher expression of many
transcripts associated with T cell function (Appendix A). For example, CD2, CD3, TRBC1,
GZMA, GZMB, TRAC, and several HLA class I and II transcripts were all significantly
higher expressed in LCK high samples. The greatest fold change was observed for
Chemokine (CXC motif) ligand 9 (CXCL9, also known as chemokine induced by interferon
γ (MIG)) with 15.64 higher expression level in the LCK high samples. Given that LCK is a
canonical T lymphocyte signaling molecule, it was surprising to find that many B
lymphocyte/plasma cell related transcripts including many immunoglobulin genes (e.g.
IGHD, IGHM, IGKC, IGLJ3, IGLC1, and IGLV1-44) were also enriched in the LCK-high
samples (Appendix A). Interestingly, CXCL13 (also known as B lymphocyte
chemoattractant (BLC)) was one of the chemokines enriched in LCK high samples (7.7 fold).

We next performed gene ontology enrichment analysis (Table 3), where genes are defined
into subsets based on functional characteristics allowing for the biologic profile of the gene
set to be obtained. This analysis confirmed that LCK high samples were significantly
enriched in B cell function and activity, as demonstrated by the highest observed-to-expected
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ratios in the “immunoglobulin complex circulating” gene ontology term (enrichment score:
46.41). In terms of molecular function, MHC II receptor activity was most closely correlated
with an enrichment score of 41.73, followed by C-C chemokine binding (29.8), and this was
mirrored in the biologic process analysis where MHC class II protein complex assembly had
the greatest enrichment (32.44, Table 3).

Given the enrichment of B-cell transcripts in LCK high samples, we also investigated the
presence of tertiary lymphoid structures (TLS) in the independent cohort of 72 HGSOC
samples. TLS represent transient colocalization of lymphoid cells in non-lymphoid tissues;
the presence of TLS has been described in multiple solid tumor types and is felt to influence
local and potentially systemic anti-cancer response. We found that LCK expression by IHC
was moderately correlated with TLS (Spearman correlation: 0.53, p= <0.0001). Proportional
hazards regression analysis was performed including both TLS and LCK as predictors of OS,
and both were significant independent predictors of survival (HRTLS = 4.1, p=0.004, HRLCK=
3.8, p=0.005). Finally, consistent with our mRNA expression analysis, there was moderate
correlation between LCK, CD20, CD8 staining, but there was no evidence of any difference
in strength of correlation between pairs of these markers (95% CI -0.18-0.28 for LCK/CD8
vs LCK/CD20 and 0.14-0.31 for CD20/CD8 vs LCK/CD8).

Given the prognostic significance of LCK positive lymphocytes in HGSOC, we next sought
to determine if the abundance of such lymphocytes differed between normal fallopian tube
epithelium (tissue of origin for the vast majority of HGSOC), benign serous neoplasms, and
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HGSOC. LCK expression was evaluated by IHC in a TMA consisting of 20 normal fallopian
tube samples, 13 serous cystadenomas, and 14 HGSOC samples. We observed higher LCK
expression in the malignant samples than in their benign counterparts (p=0.023, Appendix
B). However, LCK expressing lymphocytes were present (albeit at lower prevalence) among
normal fallopian tube epithelium samples, suggesting a possible surveillance or a tissue
resident function.

Discussion
The immunogenicity of EOC has been well documented, with extensive literature
demonstrating the presence of tumor infiltrating lymphocytes in ovarian tumors and their
prognostic significance [2]–[8]. However, the biological basis and the identification of
reliable markers for this prognostic significance have proven elusive. The original
publication of the ovarian cancer TCGA analysis identified an “immunoreactive” group as
one of the four subtypes of high grade serous ovarian cancer based on transcriptional
profiling. However, there was no prognostic impact on survival associated with this
immunoreactive subtype [18]. Recent publications have reported a histotype-specific nature
of immune infiltration and have demonstrated that the magnitude of survival benefit in
ovarian cancer was dose dependent on CD8 positive TILs [22], [23]. However, the use of
TIL for clinical decision making currently remains in its early stages, and investigation into
genomic markers have yielded mixed results.
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The need for a robust, reproducible, and immune-related biomarker in HGSOC is further
highlighted by the emerging data on immune checkpoint blockers resulting in response rates
of 10-15% in heavily pretreated patients [14], [24]–[27]. Given the low response rates and
significant toxicities of such therapies, studies aimed at identifying factors to provide more
personalized prognostication for immune response in particular are of utmost importance.
The use of PDL1 staining has emerged as a convenient and intuitive marker for prediction of
response to immune checkpoint inhibitors, at least in some cancers. However, the predictive
accuracy of this marker for ovarian cancer remains unknown. It is worth mentioning that the
response rates to PD1/PDL1 targeting monoclonal antibodies is not appreciably higher in
clinical trials that used PDL1 positivity by IHC as an eligibility criterion [26].

The current study demonstrates high LCK expression identifies a small subset of high grade
serous ovarian cancers with better PFS and OS following treatment with standard frontline
platinum-taxane adjuvant chemotherapy. LCK is an attractive biomarker as it plays a central
functional role in T-cell signaling. The T-cell receptor (TCR) is composed of an antigen
recognition subunit (TCRαβ) as well as three signaling subunits (CD3) [28]. TCR-CD3
engagement with antigen induces phosphorylation by LCK, which then triggers downstream
signaling cascades leading to antigen specific T-cell immune response. Additionally, mice
lacking LCK develop profound T cell deficiency [29]. Therefore, LCK is central to effective
and specific T-cell response, including to tumor antigen. However, LCK is demonstrated
herein to have greater discriminatory prognostic ability than previously validated metrics of
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T cell function such as CYT, which suggests it may capture additional facets of tumoral
immune response such as B cell activity.

The impact of B cell infiltrates in ovarian malignancy is less clear than their T-cell
counterparts, though they have been shown to similarly be associated with improved survival
[12], [13], [30]. The role of B cells has been supported by prior analysis of the TCGA, which
demonstrated improved survival with B-cell gene expression signatures in high grade serous
ovarian cancer [31]. The causality and mechanism of the herein reported correlation between
LCK and B cell signatures remains to be determined. Prior literature suggests B cells may
induce the maturation of dendritic cells making them competent for T-cell activation, and
preclinical studies demonstrate depletion of B cells in a mouse model results in decreased
expression of the degranulation marker CD107 on CD8+ T cells, suggesting impaired
cytotoxic response [32], [33]. Interestingly, LCK has also been implicated in B-cell signaling
at least in a minor but important B-cell subset, namely B-1 cells. These cells are found
predominantly in peritoneal and pleural cavities, which are notably the primary location of
ovarian cancer spread, and are characterized by deficient B-cell receptor (BCR) signaling
[30], [31]. In future studies we plan to further investigate the potential prognostic
significance of B1-cells and their LCK expression in HGSOC.

The limitations of the current research include small sample size, specifically due to the
stringent criteria of top 3%; the low number of LCK high tumors within the TCGA limits the
power of this analysis, specifically for gene enrichment and ontology. However, for all
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subsequent analyses, more liberal definitions of LCK high tumors were used, including top
10% for comparison with CYT and pathologic criteria for IHC in the independent cohort.
Therefore, the consistency of the association between LCK and survival lends strength to this
conclusion. For the comparison to CYT, the high and low cohorts were defined arbitrarily, as
has been done in other analyses; for example, significance of CYT in pancreas defined top
decile and compared to bottom quartile resulting in a difference in significance level [17].

In summary, this study demonstrates high LCK expression is associated with significantly
longer survival than non-high LCK tumors, and was found to be a more significant predictor
of prognosis than the previously validated cytolytic activity score (CYT) across tumor types,
including HGSOC. LCK high samples demonstrated evidence of enriched B cell infiltration
and function raising the possibility a cooperative interaction between tumor infiltrating T and
B cells is correlated with better survival in this disease. Further research is needed to better
elucidate the causality and mechanism of this correlation.
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CONCLUSION
In this study, we sought to establish genomic biomarkers in ovarian malignancy
which capture the known immunogenicity of this tumor type and its relationship to
prognosis. We utilized the Cancer Genome Atlas (TCGA) to demonstrate high LCK mRNA
expression was a strong predictor of survival in a set of 535 ovarian cancers. Patients with
high LCK mRNA expression had a longer median progression free survival (PFS) and
overall survival (OS). We then confirmed this association of LCK with survival in an
independent cohort, and importantly used less stringent cut offs for definition of high
expressing tumors which allows our findings to be generalized to a greater subset of ovarian
malignancy. Additionally, LCK expression was compared to a previously validated metric,
cytolytic activity score (CYT), in order to determine their respective prognostic capacity.
Across tumor types available in the TCGA, LCK was a more significant predictor of
prognosis; LCK was a more discerning predictor in tumor types where CYT was predictive
of OS, and it was additionally prognostic in a further subset of tumor types where CYT was
not in HGSOC.

In an attempt to generate alternate hypotheses about the mechanism for the improved
prognostic ability of LCK, we used the ovarian cancer TCGA dataset to evaluate gene
expression differences between LCK-high expressing and the remaining samples. Given that
LCK is a canonical T lymphocyte signaling molecule, it was surprising to find many B
lymphocyte/plasma cell related transcripts including many immunoglobulin genes were also
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enriched in the LCK-high samples. This research suggests a cooperative interaction between
tumor infiltrating T and B cells may correlate with better survival in this disease, and this
relationship is captured by LCK expression and is not reflected by other metrics which are
specifically T-cell focused such as CYT.

To date, most studies evaluating the prognostic significance of TILs have
concentrated on T cells, while less attention has been devoted toward TIL-B cells. In ovarian
cancer there is conflicting evidence on the association between B-cells and survival. TIL-B
cells may function to present tumor antigen to cytotoxic T cells or other immune effector
cells, and plasma cells may secrete antibodies aiding the immune response against tumor
cells. Alternatively, TIL-B subsets may function to suppress T cell anti-tumor responses (as
in Bregs) or promote tumor progression by nurturing an inflammatory microenvironment.
Therefore, it will be important to build upon the data presented herein to investigate these Bcell signatures within the TCGA. Additionally, in our independent cohort, further
investigation of tertiary lymphoid structures, which may serve as an immunohistochemical
and pathologic marker of T and B cell cooperation, should be reviewed.

The limitations of the current research include small sample size, specifically due to the
stringent criteria of top 3%; the low number of LCK high tumors within the TCGA limits the
power of this analysis, specifically for gene enrichment and ontology. However, for all
subsequent analyses, more liberal definitions of LCK high tumors were used, including top
10% for comparison with CYT and pathologic criteria for IHC in the independent cohort.
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Therefore, the consistency of the association between LCK and survival lends strength to this
conclusion. For the comparison to CYT, the high and low cohorts were defined arbitrarily,
however this is similar to the approach in other analyses.

In summary, high LCK expression is a better prognostic marker than the previously validated
cytolytic activity score (CYT) across tumor types, which we argue is due to its ability to
capture T and B cell cooperation, given that LCK high samples demonstrated evidence of
enriched B cell infiltration and function. Further research is needed to better elucidate the
causality and mechanism of this correlation. Improved understanding of these relationships
may offer valuable therapeutic approaches for the treatment of ovarian cancer, particularly in
patients with drug or immune therapy resistant disease.
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TABLES
Table 1: Demographics by LCK Expression Level
Total Cohort†
LCK High*
Non-LCK High
520
n=23
n=497
p-value
Characteristic
Age (median)
40-78 (58)
30-89 (59)
0.837
ECOG Performance
0
4
69
1
3
72
0.633
2
2
21
3
0
4
Unknown
14
331
Stage
I
1
15
II
3
25
IIIA,B
3
28
0.134
IIIC
13
366
IV
3
80
Unknown
0
4
Grade
1
0
5
2
3
61
0.552
3
19
419
Unknown
1
12
Race/Ethnicity
Asian
1
14
Black
0
23
0.4696
Hispanic
1
7
White
20
433
Other/Unknown
1
20
†
520 patients included from a total of 535 samples available
*LCK (lymphocyte specific tyrosine kinase) high: expression >1.86SD within TCGA ovarian serous
cystadenocarcinoma study (TCGA, provisional).
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Table 2: Survival Analyses Comparing the Prognostic Ability of LCK and CYT
Cancer
subtype1

ACC
BLCA
BRCA
CESC
CHOL
COAD
ESCA
GBM
HNSC
KIRC
KIRP
LAML
LGG
LIHC
LUAD
LUSC
MESO
OV
PAAD
PCPG
PRAD
READ
SARC
SKCM
STAD
TGCT
THCA
UCEC
UCS
UVM

LCK
Median OS
bottom 10%
(months)
NA
NA
90.4
19.4
24.7
NA
42.1
13.2
85.7
NA
NA
12.2
63
NA
48.5
74.1
17.6
35.3
NA
NA
NA
NA
35.4
54.3
58.2
NA
NA
NA
22.8
NA

Median OS
top 10%
(months)
NA
94.3
132
NA
NA
NA
26.1
12.5
161.9
66
NA
10.1
63.8
54.1
87.2
56
13.8
52.6
23.4
NA
NA
NA
NA
164.3
22.3
NA
NA
NA
30.4
NA

Cytolytic Activity Score (CYT)
P value
0.818
0.254
0.055
0.001
0.870
0.363
0.930
0.623
0.050
0.497
0.232
0.118
0.027
0.865
0.368
0.603
0.584
0.009
0.687
0.429
0.304
0.317
0.017
0.027
0.857
0.317
0.631
0.221
0.036
0.808

Median OS
bottom 10%
(months)
NA
NA
84.5
136
9.03
NA
26.1
13.2
28.7
NA
NA
26.4
81.1
59.7
49.7
74.1
25.2
52.8
21.7
NA
NA
NA
41.2
58.9
73.2
NA
NA
NA
31.6
NA

Median OS
top 10%
(months)
NA
NA
NA
NA
NA
NA
16.1
10.6
58.7
73
98
10.2
52.6
56.2
43.1
61.9
13.8
49.4
50.1
NA
NA
NA
NA
164.3
NA
NA
NA
NA
NA
NA

P value
0.990
0.506
0.003
0.012
0.642
0.863
0.617
0.295
0.109
0.473
0.591
0.084
0.011
0.763
0.664
0.918
0.959
0.664
0.973
0.317
0.893
0.221
0.032
0.005
0.936
0.289
0.659
0.263
0.804
0.806

Median overall survival in high LCK expression and low LCK expression as compared to
high and low CYT score. High and low groups are defined as top 10% and bottom 10%
respectively.
1

The following tumor types (project code and n=sample size) were included: adrenocortical carcinoma (ACC,
n=92), bladder/urothelial (BLCA, n=412), breast invasive carcinoma (BRCA, n=1098), cervical squamous cell
carcinoma and endocervical adenocarcinoma (CESC, n=307), cholangiocarcinoma (CHOL, n=51), colon
adenocarcinoma (COAD, n=461), esophageal carcinoma (ESCA, n = 185), glioblastoma multiforme (GBM,
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n=617), head and neck squamous cell carcinoma (HNSC, n=528), kidney renal clear cell carcinoma (KIRC,
n=537), kidney renal papillary cell carcinoma (KIRP, n=291), acute myeloid leukemia (LAML, n=200), low
grade glioma (LGG, n=516), liver hepatocellular carcinoma (LIHC, n=377), lung adenocarcinoma (LUAD, n =
585), lung squamous cell carcinoma (LUSC, n=504), mesothelioma (MESO, n=87), ovarian serous
cystadenocarcinoma (OV, n=608), pancreatic adenocarcinoma (PAAD, n=185), pheochromocytoma and
paraganglioma (PCPG, n=179), prostate adenocarcinoma (PRAD, n=500), rectum adenocarcinoma (READ,
n=172), sarcoma (SARC, n=261), skin cutaneous melanoma (SKCM, n=470), stomach adenocarcinoma
(STAD, n=443), testicular germ cell tumors (TGCT, n=150), thyroid carcinoma (THCA, n=507), uterine corpus
endometrial carcinoma (UCEC, n=560), uterine carcinosarcoma (UCS, n=57), and uveal melanoma (UVM,
n=80).
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Table 3: Gene Ontology Enrichment in selected subset (LCK high)
Cellular Component
GO ID

GO Term

GO:0042571 immunoglobulin complex, circulating
GO:0019814 immunoglobulin complex
GO:0042612 MHC class I protein complex
GO:0061702 inflammasome complex
GO:0042101 T cell receptor complex
Molecular Function
GO:0032395 MHC class II receptor activity
GO:0019957 C-C chemokine binding
GO:0046977 TAP binding
GO:0019865 immunoglobulin binding
GO:0004950 chemokine receptor activity
GO:0001637 G-protein coupled chemoattractant receptor
activity
GO:0023026 MHC class II protein complex binding
GO:0019956 chemokine binding
GO:0045236 CXCR chemokine receptor binding
GO:0023023 MHC protein complex binding
Biological Process
GO:0002399 MHC class II protein complex assembly
GO:0046113 nucleobase catabolic process
GO:0002396 MHC protein complex assembly
GO:0010818 T cell chemotaxis
GO:0002480 antigen processing and presentation of
exogenous peptide antigen via MHC class I,
TAP-independent
GO:0090026 positive regulation of monocyte chemotaxis
GO:0010819 regulation of T cell chemotaxis
GO:1901623 regulation of lymphocyte chemotaxis
GO:0036037 CD8-positive, alpha-beta T cell activation

* Observed/Expected <15.0 not reported
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Observed in
selected subset
7
7
6
6
6

Expected in
selected subset
0.15
0.22
0.26
0.3
0.39

Observed/
Expected*
46.41
32.48
23.2
19.89
15.47

7
5
6
6
8
8

0.17
0.17
0.22
0.24
0.34
0.34

41.73
29.8
26.82
24.76
23.84
23.84

6
6
6
6

0.26
0.28
0.3
0.3

22.99
21.46
20.12
20.12

5
5
5
9
5

0.15
0.18
0.18
0.39
0.23

32.44
27.8
27.8
23.35
21.62

7
5
9
5

0.36
0.26
0.49
0.31

19.46
19.46
18.44
16.22

FIGURES
Figure 1: TCGA Analysis of Immune-related Gene Expression
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Figure 2: Kaplan Meier Analysis Comparing Prognostic Ability of LCK and CYT
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Figure 3: LCK Expression and Survival Analysis in an Independent Cohort
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APPENDICES
Appendix A: Top Overexpressed Genes in LCK High Samples

Symbol

CXCL9
IGLC1
IGHM
IGKC
JCHAIN
IGKC
CXCL13
IGHM
TRBC1
IGLJ3
IGKC
CCL5
TRBC1
IGLC1
CD2
IGLJ3
CD8A
CD3D
IGLV1-44

Geometric
mean of
intensities in
class 1*

Geometric
mean of
intensities in
class 2**

55.65

870.35

15.639712

< 1e-07

< 1e-07

186.45

1984.25

10.642263

< 1e-07

< 1e-07

26.53

221

8.3301922

< 1e-07

< 1e-07

26.11

226.8

8.6863271

< 1e-07

< 1e-07

25.76

217.56

8.4456522

< 1e-07

< 1e-07

27.05

221.33

8.1822551

< 1e-07

< 1e-07

18.99

151.74

7.9905213

< 1e-07

< 1e-07

16.18

113.07

6.9882571

< 1e-07

< 1e-07

T cell receptor beta constant 1
immunoglobulin lambda
joining 3
immunoglobulin kappa
constant
chemokine (C-C motif) ligand
5

32.03

208.74

6.5170153

< 1e-07

< 1e-07

23.3

154.25

6.6201717

< 1e-07

< 1e-07

103.1

681.32

6.6083414

< 1e-07

< 1e-07

27.65

175.54

6.3486438

< 1e-07

< 1e-07

T cell receptor beta constant 1
immunoglobulin lambda
constant 1 (Mcg marker)

31.07

187.03

6.0196331

< 1e-07

< 1e-07

19.22

109.64

5.7044745

< 1e-07

< 1e-07

CD2 molecule
immunoglobulin lambda
joining 3

24.16

129.36

5.3543046

< 1e-07

< 1e-07

13.85

71.54

5.165343

< 1e-07

< 1e-07

CD8a molecule
CD3d molecule, delta (CD3TCR complex)
immunoglobulin lambda
variable 1-44

16.17

82.27

5.0878169

< 1e-07

< 1e-07

34.53

175.11

5.0712424

< 1e-07

< 1e-07

14.17

72.32

5.1037403

< 1e-07

< 1e-07

Name
chemokine (C-X-C motif)
ligand 9
immunoglobulin lambda
constant 1 (Mcg marker)
immunoglobulin heavy
constant mu
immunoglobulin kappa
constant
joining chain of multimeric
IgA and IgM
immunoglobulin kappa
constant
chemokine (C-X-C motif)
ligand 13
immunoglobulin heavy
constant mu

*Class1 = non-LCK high ** Class2 = LCK high
ᵻ Fold change < 5.0 are not reported
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Fold changeᵻ

Parametric
FDR
p-value

Appendix B: LCK Expression in Benign and Malignant Tissue

(A) LCK expression levels by immunohistochemistry staining score. Staining score defined
as: 0=none, 1=low, 2= medium, 3 = high. (B-D) Representative examples of varying LCK
expression by immunohistochemistry. B: LCK high expression in high grade serous ovarian
cancer. C: non LCK high expression (low) in high grade serous ovarian cancer. D: Moderate
LCK expression in normal fallopian tube (medium).
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